Specialty Pharmacy

The International Society for Pharmaceutical Engineering (ISPE) released its newest guide to help pharmaceutical organizations achieve and maintain control in their critical utility systems.

Leung added that this is the first study to show the potential beneficial effects of ACE inhibitors and ARBs on colorectal cancer development, based on a large group of patients who were colorectal cancer-free at the beginning of the study.

The presence of ctDNA and CTCs in the plasma of the blood of women who have undergone chemotherapy prior to surgery for the treatment of triple-negative breast cancer (TNBC) are critical indicators in the prediction of disease recurrence and disease-free survival.

Mylan plans to launch adalimumab-fkjp in the United States in July 2023.

Since 2015, there has been an increase in the number of specialty pharmacies in the United States due to their potential of handling the complexities of cost and appropriate drug access and administration.

Tofersen proves safe in clinical trials in the treatment of amyotrophic lateral sclerosis.

Regardless of the channel through which a specialty medication is billed and filled, management strategies will be an essential cornerstone to controlling costs.

According to new research published in Clinical and Translational Immunology, a new cancer vaccine is ready for human trials following its success in preclinical studies.

Regular testing for hepatitis C virus has proven more effective than targeted testing.

Pharmacy Times® interviewed Tim Safley, program director of the Accreditation Commission for Health Care (ACHC), and Jon Pritchett, program director of ACHC, on the value of specialty pharmacy and LTC accreditation for pharmacies.

The conference will take place virtually in conjunction with the eighth NASP Annual Meeting & Expo Virtual Experience.

Early and frequent screenings for childhood cancer survivors could cut breast cancer mortality by well over half.

Pharmacy Times® interviewed Tim Safley and Jon Pritchett of ACHC on evaluating the opportunities for long-term care (LTC) pharmacies in relation to specialty pharmacy accreditation.

A potential correlation between processed food and breast cancer has been discovered.

Multiple pharmacies recently received letters from ESI stating that on behalf of TRICARE and the Defense Health Agency, ESI was recouping money for compound drug claims submitted in 2015.

According to a recent study published in Gut, inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn disease, is associated with a more than doubled likelihood of developing dementia.

Urothelial carcinoma accounts for approximately 90% of all bladder cancers and becomes increasingly challenging to treat as it spreads through the layers of the bladder wall.

The development and use of specialty pharmaceuticals have significantly affected global health care practices and costs.

According to a press release, this is the first single-agent, anti-PD-1 therapy approved in the first-line environment for this patient population.

Pharmacy Times® interviewed Cory Kidd, PhD, CEO and founder of Catalia Health, on the value of technology in innovating patient care in the field of specialty pharmacy.

Erlotinib taken with gemcitabine was approved by the FDA for locally advanced, inoperable, or metastatic pancreatic cancer in 2005.

A new study found disturbing evidence that black cancer survivors are more likely to face financial hardship on high deductible health plans than their white counterparts.

Organ transplants from seropositive donors carry a high risk of infection from the transplanted organ.

Dravet syndrome is a life-threatening, rare, and chronic form of epilepsy and is often characterized by severe, unrelenting seizures despite medical treatment, according to the FDA press release.

The pharmaceutical industry is already seeing the immense benefit of AI and machine-learning technology.

Many companies are working with health systems to transition patients from the hospital to in-home care as quickly as possible.

Pharmacy Times spoke with Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, about how the drug niraparib could affect treatment options for patients with ovarian cancer.

Pembrolizumab has been approved by the FDA as a monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma.

According to the survey results, not only do a majority of the 500 respondents experience fear of bleeding events, but many of them also avoid or modify activities in order to mitigate their risk.

A recent qualitative study presented a potential explanation for why health system specialty pharmacies often find it difficult to partner with payers.